Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Wall Street Journal speculated today that it won’t be long before drug manufacturers start consolidating in order to improve their bottom lines.
Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Shares of weight-loss drugmaker Orexigen Therapeutics are in free-fall this morning after the company announced it filed for bankruptcy.
U.S. insurer Cigna is acquiring pharmacy benefits manager Express Scripts for approximately $67 billion.
In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels.
After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.
Life sciences giant Johnson & Johnson may be shopping around its sterilization products division.